Biotechnology
Global Brain Tumor Treatment Market Projected to Reach $7.15 Billion by 2035
The brain tumor treatment market is expected to experience substantial growth, driven by advances in medical technologies like immunotherapy and personalized medicine. The market's projected 7.2% compound annual growth rate signals significant potential for medical innovation and investment.
ProPhase Labs Sells Subsidiaries for $23.6M, Streamlines Business Focus
ProPhase Labs has completed the sale of its Pharmaloz subsidiaries to a private equity group, eliminating over $20 million in debt and positioning the company to concentrate on its core biotech and diagnostics businesses.
Utah's Life Sciences Showcase at State Capitol Highlights $22B Industry Growth
Utah's burgeoning life sciences sector, representing $22 billion in GDP and employing 180,000 residents, will demonstrate its economic impact and healthcare innovations to state legislators at the annual Life Sciences Day on the Hill event.
Life Science Investment Leader Michael Ryan Joins Sigyn Therapeutics Board Amid Blood Purification Tech Development
The appointment of Michael Ryan, founder of Ireland's largest angel investment syndicate, to Sigyn Therapeutics' Board of Directors strengthens the company's position in developing crucial blood purification technologies for treating life-threatening conditions.
Breakthrough Blood Test Could Revolutionize Early Stroke Treatment
A new blood test measuring brain protein levels shows promise in quickly distinguishing between bleeding and clot-based strokes before patients reach the hospital, potentially transforming emergency stroke care and improving patient outcomes.
GeoVax Embraces AI Integration in $500B Healthcare Initiative
GeoVax Labs announces comprehensive AI integration across its vaccine and immunotherapy programs as part of the Stargate Initiative, a $500 billion private-sector investment plan aimed at revolutionizing U.S. healthcare and biosecurity through advanced technologies.
Pacylex Advances Cancer Treatment Innovation with NMT Inhibitor Technology
Pacylex Pharmaceuticals is advancing its novel cancer treatment technology through major industry conferences, showcasing both oral and antibody-drug conjugate applications of their N-myristoyltransferase inhibitors, marking a significant development in targeted cancer therapy.